Durvalumab: Phase I started

The Heptares Therapeutics Ltd. subsidiary of Sosei Group Corp. (Tokyo:4565, Tokyo, Japan) said AstraZeneca began an open-label, dose-escalation, U.S. Phase I trial to evaluate twice-daily oral HTL1...